Postoperative Vocal Cord Palsy Between Double-lumen Endobronchial Tube and Bronchial Blocker for Robot-assisted Esophagectomy
Launched by SAMSUNG MEDICAL CENTER · Mar 25, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the best way to manage breathing during a specific type of surgery called robot-assisted esophagectomy, which is performed to treat esophageal cancer. The researchers want to find out if using a bronchial blocker, a device that helps keep one lung deflated during surgery, can help reduce the risk of vocal cord problems (known as vocal cord palsy) after the operation compared to a double-lumen endobronchial tube, another device used for similar purposes.
To participate in this trial, individuals must be 19 years or older and scheduled for elective robot-assisted esophagectomy due to esophageal cancer. They should be in good health (physical status I-III) and need to have certain lymph nodes removed during their surgery. However, those who already have vocal cord issues, require special breathing devices, have had previous chest surgeries, or are pregnant cannot participate. If you join the trial, you will help researchers understand which method is safer and more effective for patients undergoing this type of surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 19 or older
- • American Society of Anesthesiologists physical status I - III
- • Elective robot-assisted esophagectomy
- • Any clinical stage of esophageal cancer
- • Patients who need recurrent laryngeal nerve lymph nodes resection
- Exclusion Criteria:
- • Patients who diagnosed vocal cord palsy or damage before surgery
- • Patients who need specific airway device due to airway problem
- • History of thoracic surgery
- • Emergency surgery
- • Combined surgery with other department
- • Pregnant or nursing women
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Hyun Joo Ahn, MD PhD
Principal Investigator
Samsung Medical Center, Sungkyunkwan University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported